Cited by 217Liver physiology and pathologyLiver Disease Diagnosis and TreatmentDrug-Induced Hepatotoxicity and Protection

Modulation of Hepatic Fibrosis by c-Jun-N-Terminal Kinase Inhibition

Open access
Kluwe, Johannes, Pradere, Jean–Philippe, Gwak, Geum–Youn, Mencin, Ali, De Minicis, Samuele, Österreicher, Christoph H., Colmenero, Jordi, Bataller, Ramon +1 more·2010·Gastroenterology

Abstract

Background & aims c-Jun N-terminal kinase (JNK) is activated by multiple profibrogenic mediators; JNK activation occurs during toxic, metabolic, and autoimmune liver injury. However, its role in hepatic fibrogenesis is unknown.Methods JNK phosphorylation was detected by immunoblot analysis and confocal immunofluorescent microscopy in fibrotic livers from mice after bile duct ligation (BDL) or CCl(4) administration and in liver samples from patients with chronic hepatitis C and non-alcoholic steatohepatitis. Fibrogenesis was investigated in mice given the JNK inhibitor SP600125 and in JNK1- and JNK2-deficient mice following BDL or CCl(4) administration. Hepatic stellate cell (HSC) activation was determined in primary mouse HSCs incubated with pan-JNK inhibitors SP600125 and VIII.Results JNK phosphorylation was strongly increased in livers of mice following BDL or CCl(4) administration as well as in human fibrotic livers, occurring predominantly in myofibroblasts. In vitro, pan-JNK inhibitors prevented transforming growth factor (TGF) beta-, platelet-derived growth factor-, and angiotensin II-induced murine HSC activation and decreased platelet-derived growth factor and TGF-beta signaling in human HSCs. In vivo, pan-JNK inhibition did not affect liver injury but significantly reduced fibrosis after BDL or CCl(4). JNK1-deficient mice had decreased fibrosis after BDL or CCl(4), whereas JNK2-deficient mice displayed increased fibrosis after BDL but fibrosis was not changed after CCl(4). Moreover, patients with chronic hepatitis C who displayed decreased fibrosis in response to the angiotensin receptor type 1 blocker losartan showed decreased JNK phosphorylation.Conclusions JNK is involved in HSC activation and fibrogenesis and represents a potential target for antifibrotic treatment approaches.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2009.09.015

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kluwe, J., Pradere, J., Gwak, G., Mencin, A., De Minicis, S., Österreicher, C. H., Colmenero, J., Bataller, R., & Schwabe, R. F.
Affiliations
  • Columbia University (US)
  • Hospital Clínic de Barcelona (ES)
Corresponding author
Schwabe, Robert F.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2010-01
Volume
138
Issue
1
Pages
347-359
ISSN
0016-5085 (ISSN-L)
OpenAlex
W2126503463
Cited by
217
References
45
Citations by year
2026: 6 · 2025: 7 · 2024: 8 · 2023: 13 · 2022: 15 · 2021: 24 · 2020: 8 · 2019: 10 · 2018: 13 · 2017: 17 · 2016: 15 · 2015: 6 · 2014: 19 · 2013: 16 · 2012: 16
FWCI
8.62
Type
journal article
Language
en
Open access
Locations
  • Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
Funders
American Liver Foundation
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords
c-Jun N-terminal kinase, liver fibrosis, hepatic stellate cell activation, JNK1, JNK2, SP600125, bile duct ligation, carbon tetrachloride, chronic hepatitis C, nonalcoholic steatohepatitis, TGF-beta signaling, platelet-derived growth factor, angiotensin II, losartan, antifibrotic therapy, myofibroblasts
MeSH terms
Angiotensin II, Animals, Anthracenes, Carrier Proteins, Cell Division, Cells, Cultured, Disease Models, Animal, Fatty Liver, Fibroblasts, Humans, Liver Cirrhosis, Membrane Glycoproteins, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Mutant Strains, Phosphorylation, Platelet-Derived Growth Factor, Transforming Growth Factor beta, Hepatitis C, Chronic, Protein Kinase Inhibitors, Mitogen-Activated Protein Kinase 9, Mice, Hepatic Stellate Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review